| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS46001062 | BKPyv | ENSG00000112964.14 | protein_coding | GHR | No | No | 2690 | A0A087X0H5 A0A087X162 P10912 |
| TVIS46001286 | BKPyv | ENSG00000112964.14 | protein_coding | GHR | No | No | 2690 | A0A087X0H5 A0A087X162 P10912 |
| TVIS10005296 | HBV | ENSG00000112964.14 | protein_coding | GHR | No | No | 2690 | A0A087X0H5 A0A087X162 P10912 |
| TVIS10005297 | HBV | ENSG00000112964.14 | protein_coding | GHR | No | No | 2690 | A0A087X0H5 A0A087X162 P10912 |
| TVIS10011806 | HBV | ENSG00000112964.14 | protein_coding | GHR | No | No | 2690 | A0A087X0H5 A0A087X162 P10912 |
| TVIS10011807 | HBV | ENSG00000112964.14 | protein_coding | GHR | No | No | 2690 | A0A087X0H5 A0A087X162 P10912 |
| TVIS10050761 | HBV | ENSG00000112964.14 | protein_coding | GHR | No | No | 2690 | A0A087X0H5 A0A087X162 P10912 |
| TVIS10049007 | HBV | ENSG00000112964.14 | protein_coding | GHR | No | No | 2690 | A0A087X0H5 A0A087X162 P10912 |
| TVIS10049259 | HBV | ENSG00000112964.14 | protein_coding | GHR | No | No | 2690 | A0A087X0H5 A0A087X162 P10912 |
| TVIS30082890 | HIV | ENSG00000112964.14 | protein_coding | GHR | No | No | 2690 | A0A087X0H5 A0A087X162 P10912 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | GHR |
|---|---|
| DrugBank ID | DB00082 |
| Drug Name | Pegvisomant |
| Target ID | BE0000075 |
| UniProt ID | P10912 |
| Regulation Type | antagonist |
| PubMed IDs | 19820031; 17322491; 11752352; 20595800 |
| Citations | Moller L, Norrelund H, Jessen N, Flyvbjerg A, Pedersen SB, Gaylinn BD, Liu J, Thorner MO, Moller N, Lunde Jorgensen JO: Impact of growth hormone receptor blockade on substrate metabolism during fasting in healthy subjects. J Clin Endocrinol Metab. 2009 Nov;94(11):4524-32. doi: 10.1210/jc.2009-0381. Epub 2009 Oct 9.@@Paisley AN, Hayden K, Ellis A, Anderson J, Wieringa G, Trainer PJ: Pegvisomant interference in GH assays results in underestimation of GH levels. Eur J Endocrinol. 2007 Mar;156(3):315-9.@@Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.@@De Martino MC, Auriemma RS, Brevetti G, Vitale G, Schiano V, Galdiero M, Grasso L, Lombardi G, Colao A, Pivonello R: The treatment with growth hormone receptor antagonist in acromegaly: effect on vascular structure and function in patients resistant to somatostatin analogues. J Endocrinol Invest. 2010 Oct;33(9):663-70. doi: 10.3275/7143. Epub 2010 Jul 1. |
| Groups | Approved |
| Direct Classification | Peptides |
| SMILES | |
| Pathways | |
| PharmGKB | PA164749630 |
| ChEMBL | CHEMBL1201515 |
